18F−Prostate−Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN−2): a phase I/II study

Puik, Jisce R.; Poels, Thomas T.; Hooijer, Gerrit K. J.; Cysouw, Matthijs C. F.; Verheij, Joanne; Wilmink, Johanna W.; Giovannetti, Elisa; Kazemier, Geert; Sarasqueta, Arantza Farina; Oprea-Lager, Daniela E.; Swijnenburg, Rutger-Jan

doi:10.1186/s40644-025-00822-y

Table 1 Patient characteristics and PSMA expression

From: ¹⁸F−Prostate−Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN−2): a phase I/II study

N	Age	Sex	Tumor location	Histology	Origin	pTNM stage^a	Locoregional lymph nodes^b	Tumor differentiation	DM (mm)^c	PSMA uptake^d	Visual score^e	SUVmax	TBR	PSMA + /ERG + (%)	Staining vessels	Acinar parenchyma
1	71	F	head	ductal adenocarcinoma	uncertain	T2N2	3/8	intermediate	28	yes	3	4.48	2.91	30–40	+	-
2	66	F	body-tail	ductal adenocarcinoma	pancreas	T2N1	2/9	intermediate	33	yes	2	5.40	2.38	20–30	+	-
3	68	F	juxta-papillary	carcinoma	uncertain	n.a	0/22	undifferentiated	41	yes	2–3	7.07	2.24	60	+	-
4	70	M	uncinate process	liver biopsy: adenocarcinoma	likely pancreas	TxNxM1	unknown	unknown	18	yes	3	6.83	3.69	10–12	+	n.a
5	66	F	pancreaticoduodenal groove	adenocarcinoma	duodenum	T3N0	0/16	intermediate	65	yes	1–2	4.00	2.56	30–40	+	-
6	76	F	head	ductal adenocarcinoma	pancreas	T1bN0	0/24	well	16	yes	2–3	6.72	3.63	10	+ +	-
7	74	M	head	adenocarcinoma in IPMN	pancreas	T1cN2	7/16	well	19	no	0	n.a	n.a	10–20	+	-
8	73	F	head	ductal adenocarcinoma	pancreas	T1cN0	0/19	intermediate	14	yes	3	5.43	4.18	40	+	-
9	70	M	uncinate process	non-invasive IPMN, intestinal type	pancreas	n.a	0/28	n.a	n.a	yes	1	5.07	5.28	10	+	-
10	66	F	head	ductal adenocarcinoma	pancreas	T1cN1	1/13	intermediate	20	yes	1	3.70	2.72	70	+ +	-
11	78	M	head	adenocarcinoma	CBD	T2N0	0/25	poor	28	yes	2	5.77	2.81	10	+ / + +	-
12	73	M	body-tail	ductal adenocarcinoma	pancreas	T3N1	2/29	intermediate	70	yes	1	3.30	2.10	5	+	-
13	70	M	head	ductal adenocarcinoma	uncertain, likely pancreas	T2N0	0/13	intermediate	28	no	0	n.a	n.a	10	+	-
14	57	M	head	intraoperative biopsy liver: adenocarcinoma	likely pancreas	TxNxM1	unknown	unknown	40	no	0	n.a	n.a	0	-	n.a
15	60	M	body	ductal adenocarcinoma	pancreas	T2N1	1/13	poor	22	yes	1	3.93	2.67	40–50	+ / + +	n.a
16	77	F	tail	ductal adenocarcinoma	pancreas	T2N2	8/18	intermediate	28	no	0	n.a	n.a	0	-	-
17	54	M	head	ductal adenocarcinoma	pancreas	T2N2	11/16	intermediate	38	yes	2	5.66	6.36	70–80	+ +	-

Abbreviations PSMA Prostate-specific membrane antigen, N Number, F Female, M Male, IPMN Intraductal papillary mucinous neoplasm, CBD Common bile duct, pTNM stage Pathological tumor-nodal-metastasis stage, n.a not applicable, DM Diameter, SUVmax maximum standardized uptake value, TBR Tumor-to-background ratio, ERG Erythroblastosis virus E26 transformation specific-related gene
^aPathological TNM stage according to the 8th Edition UICC TNM Classification of Malignant Tumours
^bPositive lymph node ratio, defined as ratio of positive lymph nodes to all lymph nodes
^cDiameter measured at pathological examination
^dRadiological PSMA tracer uptake that visually exceeded the blood pool uptake
^eVisual score in accordance with EANM guidelines, in which 0 is defined as no tracer uptake, 1 as weak uptake, 2 as intermediate uptake, and 3 as strong uptake

Back to article page

ISSN: 1470-7330

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Imaging

Contact us